trending Market Intelligence /marketintelligence/en/news-insights/trending/zeCpvZ1nML7obyVxPytEYA2 content esgSubNav
In This List

Generex merging NuGenerex with public company to complete planned spinout

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Generex merging NuGenerex with public company to complete planned spinout

Generex Biotechnology Corp. is merging its subsidiary NuGenerex Immuno-Oncology with a public company to complete a planned spinout.

Miramar, Fla.-based Generex expects to list the spinout on a public exchange by the end of November. The public company was not named in an Oct. 15 press release.

The merger is part of Generex's go-public strategy to gain value from the Ii-Key technology and AE37 immunotherapeutic vaccine program. Generex announced plans to spin out the NuGenerex subsidiary into a separate publicly traded company in January.

Generex in June signed a letter of intent to merge NuGenerex Immuno-Oncology with Lubbock, Texas-based private company Kiromic LLC in an all-stock transaction.

NuGenerex Immuno-Oncology, which is focused on developing immunotherapies to treat cancer, infectious diseases and autoimmune disorders, is currently conducting a phase 2 study to determine the recommended dose for AE37 Peptide Vaccine in combination with Merck & Co. Inc.'s Keytruda for the treatment of patients with advanced triple-negative breast cancer.